The authors regret that four incorrect estimates pertaining to adverse event (AE) incidence were stated in the text, discrepant from the corresponding tables where correct estimates were included. Specifically, incorrect values were stated in the text for incidence of the following treat treatment-related AEs: 1) AEs of any grade, 2) grade 3-4 AEs, 3) grade 3-4 AST events, and 4) grade 3-4 ALT events. Correct values were included the corresponding supplemental tables 2 and 4, and are stated here: Treatment-related AEs of any grade were experienced by 40 patients (100%); grade 3-4 AEs were experienced by 20 patients (50%). Treatment-related grade 3-4 AST and ALT elevations were 13% and 15% respectively.

中文翻译：

---

“卡博替尼联合纳武利尤单抗治疗非透明细胞肾细胞癌患者：II 期试验的最新结果”的勘误 [Eur. Urol. 86（2） （2024） 90–94]


遗憾的是，文中陈述了四个与不良事件 （AE） 发生率有关的错误估计值，与包含正确估计值的相应表格不一致。具体来说，文中对以下治疗相关 AE 的发生率陈述的值不正确：1） 任何级别的 AE，2） 3-4 级 AE，3） 3-4 级 AST 事件，以及 4） 3-4 级 ALT 事件。相应的补充表 2 和 4 中包含了正确的值，如下所示：40 名患者 （100%） 经历了任何级别的治疗相关 AE;20 名患者 （50%） 经历了 3-4 级 AE。治疗相关的 3-4 级 AST 和 ALT 升高分别为 13% 和 15%。